Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWVS5X)

Drug Name
JWH-250 Drug Info
Synonyms
864445-43-2; 2-(2-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; JWH-250; 2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone; UNII-IP9911R8A0; CHEMBL188031; FFLSJIQJQKDDCM-UHFFFAOYSA-N; IP9911R8A0; Q-200139; 1-Pentyl-3-(2-methoxyphenylacetyl)indole; DEA No. 6250; SCHEMBL11983322; CTK8C5059; JWH 250; DTXSID40235556; MolPort-009-019-586; KS-000024QU; ANW-73903; ZINC28465020; MFCD12911796; BDBM50170335; AKOS015999864; DS-3158; CCG-208724; NCGC00386575-01; AJ-83461; CJ-17680; AK-82232; AN-26990; KB-110367; TC-162648; ST24021676
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44397540
CAS Number
CAS 864445-43-2
TTD Drug ID
DMWVS5X

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Cannabinoid receptor 2 (CB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Guanfacine extended release DMB1CZ8 Attention deficit hyperactivity disorder 6A05.Z Approved [2]
NABILONE DMVRYT2 Insomnia 7A00-7A0Z Approved [3]
GW-42004 DMY3KSU Lipid metabolism disorder 5C52.Z Phase 2 [4]
KHK-6188 DMF6CTI Neuropathic pain 8E43.0 Phase 2 [5]
LY-2828360 DMO8IEZ Pain MG30-MG3Z Phase 2 [5]
APD371 DM3XT5V Crohn disease DD70 Phase 2 [6]
S-777469 DMZGNOJ Atopic dermatitis EA80 Phase 2 [7]
842166X DMOV0AP Pain MG30-MG3Z Phase 2 [8]
Beta-caryophyllene DM7583A Pain MG30-MG3Z Phase 2 [9]
Vicasinabin DMF16CU Diabetic retinopathy 9B71.0 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cannabinoid receptor 2 (CB2) TTMSFAW CNR2_HUMAN Inhibitor [1]

References

1 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
2 Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81.
3 Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
4 Company report (Gwpharm)
5 Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2).
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79.
8 The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies. Yao Xue Xue Bao. 2013 Sep;48(9):1436-49.
9 The cannabinoid CB1 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20.
10 Clinical pipeline report, company report or official report of Roche